TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. In September, the company announced that 200 out of 243 expected patients had been enrolled in its ongoing study evaluating the effectiveness of Berubicin for recurrent glioblastoma (“GBM”), a highly aggressive and incurable form of brain cancer. The critical and adaptive global trial involves multiple centers and is open-label, randomized and controlled, comparing Berubicin to Lomustine - the standard of care - in adult patients with recurrent GBM (“WHO Grade IV”) after standard first-line therapy has failed. The…